Zacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $19.60 Million

Share on StockTwits

Wall Street analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report sales of $19.60 million for the current quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The lowest sales estimate is $19.00 million and the highest is $21.25 million. BioDelivery Sciences International posted sales of $11.28 million in the same quarter last year, which would indicate a positive year over year growth rate of 73.8%. The firm is expected to issue its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full-year sales of $100.71 million for the current fiscal year, with estimates ranging from $98.60 million to $105.80 million. For the next year, analysts expect that the business will report sales of $141.39 million, with estimates ranging from $135.15 million to $149.70 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. The company had revenue of $18.03 million during the quarter, compared to analysts’ expectations of $16.15 million.

Several research firms have recently issued reports on BDSI. BidaskClub cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald restated a “buy” rating and set a $8.00 target price on shares of BioDelivery Sciences International in a report on Tuesday. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. SunTrust Banks began coverage on BioDelivery Sciences International in a report on Tuesday, March 19th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of BioDelivery Sciences International in a report on Friday, March 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. BioDelivery Sciences International currently has an average rating of “Buy” and an average target price of $5.79.

Shares of BioDelivery Sciences International stock traded down $0.34 during trading on Friday, hitting $4.51. 30,244 shares of the stock were exchanged, compared to its average volume of 1,096,591. The stock has a market cap of $341.28 million, a P/E ratio of -6.18 and a beta of 0.46. BioDelivery Sciences International has a 12-month low of $1.70 and a 12-month high of $5.37. The company has a current ratio of 3.07, a quick ratio of 2.82 and a debt-to-equity ratio of 1.74.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $4.60, for a total value of $36,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 9,050 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $5.20, for a total value of $47,060.00. Following the completion of the sale, the director now directly owns 2,509,005 shares of the company’s stock, valued at $13,046,826. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,048,050 shares of company stock worth $10,241,990. 13.26% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. Stonepine Capital Management LLC raised its position in shares of BioDelivery Sciences International by 190.1% in the 3rd quarter. Stonepine Capital Management LLC now owns 4,311,103 shares of the specialty pharmaceutical company’s stock worth $12,071,000 after acquiring an additional 2,825,101 shares in the last quarter. Nantahala Capital Management LLC increased its position in BioDelivery Sciences International by 64.0% during the 4th quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock valued at $10,114,000 after buying an additional 1,066,900 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of BioDelivery Sciences International by 150.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock worth $4,200,000 after purchasing an additional 900,000 shares in the last quarter. Millennium Management LLC increased its holdings in shares of BioDelivery Sciences International by 703.6% in the 4th quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock worth $3,631,000 after purchasing an additional 859,292 shares in the last quarter. Finally, Pura Vida Investments LLC bought a new stake in shares of BioDelivery Sciences International in the 4th quarter worth $2,305,000. 57.09% of the stock is owned by institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply